| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 896 |
| 1 | CYCLOPHOSPHAMIDE | 877 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 877 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 877 |
| 4 | PREDNISOLONE | 622 |
| 5 | PREDNISOLONE ORAL | 622 |
| 6 | PREDNISOLONE ORAL SOLUTION | 622 |
| 7 | DOXORUBICIN | 543 |
| 8 | PREDNISONE | 508 |
| 9 | LAMIVUDINE | 507 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | THALLOUS CHLORIDE, TL 201 | 4 | 0.0784 |
| 1 | CABOTEGRAVIR SODIUM | 65 | 0.0405 |
| 2 | HEPATITIS B IMMUNE GLOBULIN (HUMAN) | 2 | 0.0392 |
| 3 | ADEFOVIR DIPIVOXIL | 47 | 0.0370 |
| 4 | ENTECAVIR | 332 | 0.0281 |
| 5 | TENOFOVIR DISOPROXIL FUMARATE TABLETS | 201 | 0.0232 |
| 6 | LAMIVUDINE | 507 | 0.0201 |
| 7 | TAFASITAMAB-CXIX | 12 | 0.0132 |
| 8 | RILPIVIRINE | 92 | 0.0129 |
| 9 | EPLONTERSEN | 2 | 0.0114 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Human Immunoglobulin [EPC] | 2 | 0.0392 |
| 1 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 786 | 0.0160 |
| 2 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 662 | 0.0060 |
| 3 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 110 | 0.0046 |
| 4 | Alkylating Drug [EPC] | 931 | 0.0038 |
| 5 | Tubulin Inhibiting Agent [EPC] | 1 | 0.0034 |
| 6 | CD20-directed Cytolytic Antibody [EPC] | 965 | 0.0030 |
| 7 | CCR5 Co-receptor Antagonist [EPC] | 6 | 0.0026 |
| 8 | Histone Deacetylase Inhibitor [EPC] | 10 | 0.0026 |
| 9 | Interleukin-36 Receptor Antagonist [EPC] | 1 | 0.0025 |